SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal antibodies using its proprietary transchromosomic bovine platform, branded DiversitAb. The company went public in October 2021 through a merger with Big Rock Partners Acquisition Corp, a SPAC sponsored by Big Rock Partners LLC, which had completed its IPO in 2020. SAB Biotherapeutics operates within the biotechnology and immunology sector, advancing therapeutic candidates targeting infectious diseases and other critical conditions. The company continues to file periodic reports with the SEC, including its 10-Q for the quarter ended March 31, 2026, filed May 12, 2026. For full financials, pipeline data, and SPAC deal history on SABS, sign up for complete coverage on SpacDesk.